Drug profile · INN
norgestimate
TRI-LO-LINYAH
norgestimate (TRI-LO-LINYAH) is a progesterone receptor agonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — norgestimate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
norgestimate (TRI-LO-LINYAH) is a progesterone receptor agonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Progesterone receptor agonist
Primary target: Progesterone receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is norgestimate?
norgestimate (TRI-LO-LINYAH) is a progesterone receptor agonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for norgestimate?
TRI-LO-LINYAH is a marketed brand name for norgestimate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of norgestimate?
norgestimate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.